Similar articles

• Novel antidepressant strategies to optimize outcome.

  [No authors listed] [No authors listed] J Clin Psychiatry. 2000 Sep;61(9):686-96. doi: 10.4088/jcp.v61n0916. J Clin Psychiatry. 2000. PMID: 11030494 No abstract available.
• Introduction. Reboxetine: a new selective antidepressant for the treatment of depression.

  Montgomery SA, Schatzberg AF. Montgomery SA, et al. J Clin Psychiatry. 1998;59 Suppl 14:3. J Clin Psychiatry. 1998. PMID: 9818622 No abstract available.
• The clinical pharmacologic profile of reboxetine: does it involve the putative neurobiological substrates of wellbeing?

  Healy D, Healy H. Healy D, et al. J Affect Disord. 1998 Dec;51(3):313-22. doi: 10.1016/s0165-0327(98)00227-4. J Affect Disord. 1998. PMID: 10333985 Review.
• [Depressed, lacking motivation, unconcentrated. Signs of central deficiency of noradrenaline].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2004 Jul 8;146(27-28):56. MMW Fortschr Med. 2004. PMID: 15526675 German. No abstract available.
• The need for new and better antidepressants: reboxetine a new option.

  Dencker SJ. Dencker SJ. Acta Psychiatr Scand Suppl. 2000;402:6-11. doi: 10.1034/j.1600-0447.2000.02602.x. Acta Psychiatr Scand Suppl. 2000. PMID: 10901153 Review.